PROTAGONIST THERAPEUTICS, INC.
7707 GATEWAY BLVD., SUITE 140
Newark, California 94560
(510) 474-0170
November 20, 2019
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: | Jeffrey Gabor | |
|
| |
Re: | Protagonist Therapeutics, Inc. | |
| Registration Statement on Form S-3 | |
| File No. 333-234414 | |
|
| |
| Acceleration Request | |
| Requested Date: | Friday, November 22, 2019 |
| Requested Time: | 4:00 p.m., Eastern Time |
Ladies and gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the Registration Statement on Form S-3 (File No. 333-234414) (the “Registration Statement”) to become effective on Friday, November 22, 2019, at 4:00 p.m., Eastern Time, or as soon as practicable thereafter, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission (the “Staff”). The Registrant hereby authorizes each of Michael E. Tenta and Peter N. Mandel of Cooley LLP, counsel to the Registrant, to make such request on its behalf.
Once the Registration Statement has been declared effective, please orally confirm that event with Michael E. Tenta of Cooley LLP, counsel to the Registrant, at (650) 843-5636, or in his absence, Peter N. Mandel at (415) 693-2102.
In connection with this request, the Registrant acknowledges that:
· should the Commission or the Staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
· the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
· the Registrant may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
| Very truly yours, | |
|
| |
| Protagonist Therapeutics, Inc. | |
|
| |
| By: | /s/ Don Kalkofen |
| Name: | Don Kalkofen |
| Title: | Chief Financial Officer |
cc: Dinesh V. Patel, Ph.D., Protagonist Therapeutics, Inc.
Michael E. Tenta, Cooley LLP
Peter N. Mandel, Cooley LLP
